EMBCEmbecta Corp.

$6.70-52% 1Y

$6.70

$2.8952 weeks$14.20

Is the price fair?

Good

Undemanding: modest expectations priced in and cheap against its own history.

2 good, 1 without data

What the price assumes~−27% a yearderived · Jun 30, 2026

Priced for a decline (~−27% a year). Little growth is priced in even as revenue fell 3% a year over three years, potential value, or a value trap.

Vs its own P/E rangecheaper than 88% of its own historyderived

Cheap vs its own history: P/E 4.6 vs a 9.6 median over 17 quarters (−52% vs median).

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Embecta Corp. trades at 4.56× earnings against 40.7× for the median Medical Instruments & Supplies name, cheaper than its own group.

4.56

Trailing P/E · Medical Instruments & Supplies median 40.7 · cheaper than the typical name in its group

Price / sales: 0.19
Price / sales · as of 2026-Q2
Free cash flow yield: 43%
Free cash flow yield · Medical Instruments & Supplies median 3.6%
Growth the price implies: −27%
Growth the price implies · The price pays for −27% free cash flow growth a year for a decade; the business has delivered +33% a year over the last three.

Details›

EMBC has re-rated away from its own history, so multiplying the old multiple by today's earnings prices a full reversal, not the business
Method	Per share
What its own history would imply	not meaningful, 4.56× today against a 9.58× median
52-week range	$2.89 – $14.20
Today	$6.70

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.

Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.

Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.

Ranks #3 of 20 by RyuScore